查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1836790

全球非侵入性产前检测市场预测（2025-2032 年），按检测类型、技术、怀孕、分娩方式和最终用户划分

Non-invasive Prenatal Testing Market by Test Type, By Technology, Gestation Period, Mode of Delivery, End-User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，非侵入性产前检测市场规模将成长至 145.2 亿美元，复合年增长率为 11.05%。

主要市场统计数据
基准年2024年 62.7亿美元
预计2025年 69.3亿美元
预测年份：2032年 145.2亿美元
复合年增长率（%） 11.05%

结合临床进展、病患期望和产前检测的操作挑战，建构当代非侵入性产前检测格局

非侵入性产前检测已从一种小众的筛检辅助手段发展成为产前护理的核心支柱，这得益于定序、生物资讯学以及日益以患者为中心的医疗保健生态系统的进步。如今，临床医生依靠游离DNA分析来指导怀孕早期的诊断途径，而准父母则期望获得更清晰的咨询和更少侵入性的选择。因此，临床界和相关人员需要在技术能力、监管监督和支付方接受度的交汇处应对快速变化的局面。

因此，产科环境要求严谨的证据生成，并周全地整合实验室工作流程和产科护理。实验室正在平衡精准度和通量，医院正在重新调整产前咨询通讯协定，专科诊所正在改善病患参与模式，以反映临床效用和伦理考量。此外，随着诊断复杂程度的提高，确保公平取得、结果清晰以及强有力的检测后追踪的责任也随之增加。本引言概述了更广泛的市场力量和临床需求，这些需求构成了后续分析和建议的基础。

技术的快速成熟、检体收集的分散化以及不断变化的监管预期如何从根本上重新定义产前诊断护理的提供

过去几年，在技术融合和医疗服务模式转变的推动下，非侵入性产前检测发生了变革性的变化。次世代定序平台和更复杂的生物资讯演算法将检测能力扩展到常见的三体性之外，从而能够以更高的分辨率识别更广泛的染色体异常和微缺失。同时，检测设计和实验室自动化的改进缩短了周转时间并提高了可重复性，从而加快了临床决策速度并简化了与产前工作流程的整合。

同时，市场正朝着分散样本采集和患者参与的方向转变。家用样本试剂套件和就地检验的普及为更早获取和更便捷的检测提供了机会，但也引发了有关品管、病患教育和资料安全的新问题。在服务提供方式改变的同时，监管机构和付款方也逐步改善覆盖框架和证据要求。监管的成熟，加上临床检验研究的扩展，正在鼓励更广泛的临床应用，同时也提高了製造商和实验室在临床效用和成本效益方面的标准。这些转变不仅仅是渐进的；它们正在重新定义产前筛检在多个护理点的提供、解读和执行方式。

评估新进口关税对营运、供应链和付款人层面的影响，这些影响正在重塑产前检测的成本结构和策略采购决策

2025年，美国将对某些进口检测设备、耗材和试剂征收关税，这为非侵入性产前检测的经济性带来了新的变数。对于依赖全球供应链供应定序仪、试剂和精密光学元件的实验室和设备製造商而言，关税引发的成本调整已导致其营业利润率下降，并使其筹资策略面临新的审查。许多地方的组织机构正在采取应对措施，包括审查库存管理实践、与供应商协商长期合同，以及加快关于供应链弹性和近岸外包的讨论。

除了眼前的成本压力外，关税还刺激了围绕在地化製造和多元化采购的策略性思考。垂直整合的公司以及那些能够取代国内投入的公司获得了相对的营运弹性。此外，关税环境正在鼓励製造商和付款人之间加强合作，并刺激报销结构重组，因为相关人员正在就如何在不损害临床品质的情况下维持患者可及性达成共识。最后，这种政策环境凸显了透明的成本沟通和积极主动的监管参与的重要性，以减轻对检测可用性、实验室整合和创新轨蹟的下游影响。

将检测类型、技术平台、孕龄、分娩模式和临床最终用户联繫起来的细粒度細項分析，以发现策略机会区

市场区隔洞察揭示了临床需求、技术能力和服务产品的交集，以创建差异化的价值提案。根据测试类型，市场分为非整倍体筛检，包括三体综合征，如 13 三体（帕陶综合征）、18 三体（爱德华兹综合征）和 21 三体综合征（唐氏症） ；微缺失症候群，如 1p36 缺失、22q11.2 缺失（柯林菲特氏症氏症候群）和猫哭症候群；症候群（XXX）、透纳氏症（单体 X）和 XYY 症候群；以及拓宽检测范围的全基因组筛检方法。每种测试类型对分析灵敏度、咨询复杂性和确认工作流程都有不同的要求，这会影响实验室结构和临床应用。

从技术面来看，竞争集中在基于微阵列的分析、次世代定序、聚合酵素链锁反应技术和滚环扩增技术上。这些技术不仅在分析通量和每个样本的成本上有所不同，而且在生物资讯学的复杂性和预期验证上也有所不同，从而导致不同的购买重点和伙伴关係策略。考虑到孕週，细分为 10-17 週、18-23 週和 >23 週会影响临床效用。依家庭检体采集、实验室检测服务和就地检验的配送方式进行细分，可以揭示不同的营运模式和患者体验权衡。最后，对最终用户（包括诊断实验室、医院和专科诊所）的细分揭示了检测量、临床路径和预期服务水平的差异，从而影响销售管道、付款人互动和临床教育策略。对这些细分市场的综合分析揭示了技术创新和商业性重点可以在哪些方面产生最大的临床和经济影响。

美洲、欧洲、中东和非洲以及亚太地区的细微采用模式和政策将决定差异化的市场进入和服务模式

区域动态持续影响非侵入性产前检测的采用模式、监管预期和商业策略。在美洲，成熟的报销框架、产科护理提供者的高临床采用率以及充满活力的商业检测格局，正在推动人们关注临床效用研究、付款人参与度和服务差异化。该地区的市场参与企业通常优先考虑与医疗保健系统建立伙伴关係，并投资于快速检测吞吐量，以满足临床需求，同时解决服务欠缺地区对公平获取医疗服务的担忧。

相反，欧洲、中东和非洲 (EMEA) 是一个异质环境，管理体制和付款人模式差异很大，需要量身定制的证据生成和市场准入方法。虽然一些欧洲市场的集中式公共医疗保健系统强调成本效益和与国家指南的一致性，但中东和非洲部分地区面临基础设施和准入限制，需要製定以能力建设和临床医生教育为中心的策略。与此同时，亚太地区正在经历快速的都市区采用、商业实验室网络的扩展以及对本地製造和基因组学能力的投资增加。该地区的早期进入者优先考虑服务本地化、多语言病人参与以及与区域卫生当局合作以扩大准入。在所有地区，跨境合作、资料隐私考量以及对文化上合适的咨询的需求都是公司必须深思熟虑地解决的反覆出现的主题。

垂直整合、验证主导的差异化、策略伙伴关係和选择性整合的竞争动态塑造了产前诊断领域的公司策略

活跃于非侵入性产前检测领域的公司之间的竞争行为以垂直整合、平台差异化和策略伙伴关係关係相结合为特征。大型诊断公司和临床实验室正在投资于检测检验、生物资讯学改进和临床适应症扩展，以加强其实证定位。同时，随着各机构寻求捆绑解决方案以减少医院系统和大型实验室网路的实施摩擦，仪器製造商、试剂供应商和临床服务供应商之间的联盟也变得越来越普遍。

同时，规模较小的创新企业正专注于家庭采集平台、增强型病患报告介面或专门的微缺失侦测面板，开拓利基市场。随着市场参与企业透过收购来保护智慧财产权、扩大地域覆盖范围或加速进入相关检测模式，整合趋势显而易见。重要的是，合规性和第三方认证仍然是差异化因素。那些展现出严格临床检验、透明性能特征和稳健品质系统的公司通常会获得医疗保健购买者和付款人的优先待遇。整体而言，竞争格局青睐那些将科学严谨性与扩充性营运和清晰报销途径相结合的公司。

诊断领导者可采取的策略重点，以同时增强临床检验、供应弹性、付款人参与度和以病人为中心的交付模式

产业领导者必须采取一系列多管齐下的行动，在保持临床可信度的同时，抓住商业性机会。首先，投资严格的临床检验研究和真实世界证据项目，将增强其在付款人和临床医生中的影响力，并促进更广泛地采用指南。其次，多元化供应链并建立更牢固的供应商关係可以减轻进口关税和零件短缺的影响。企业也应尽可能评估近岸外包和多供应商策略，以维持营运的连续性。

第三，公司应优先考虑以患者为中心的服务模式，以改善可及性和吸收率，例如扩大家庭采集计画并结合临床医生介导的咨询途径。第四，透过循证价值记录和结果数据加强付款人参与对于确保永续报销至关重要。同时，公司应在其实验室中追求可扩展的自动化，并投资于可互通的数据系统，以加快週转时间并降低每次测试的营运成本。最后，探索策略伙伴关係关係和有针对性的併购，以获得缺失的能力，例如生物资讯学、样本采集和区域市场进入，可以加快上市时间并最大限度地降低执行风险。这些建议创造了一个平衡临床严谨性和商业性实用性的营运方案。

我们严格的多源调查方法，结合专家访谈、临床文献综合和反覆检验，支持我们可靠的市场洞察和建议。

此调查方法整合了主要相关人员访谈、二手文献综合和方法论三角检验，以确保得出平衡且可论证的结论。初步研究涉及与临床遗传学家、实验室主任、产科负责人和公司高管进行结构化对话，以了解当前的实践模式、采购重点和创新蓝图。此外，我们还对同行评审的临床研究、监管指南和已发表的技术摘要进行了系统性回顾，以检验分析性能属性和临床效用描述，从而补充了这些见解。

透过与专家进行反覆检验，对数据进行交叉核对，以完善实验室工作流程、技术采用障碍和当地政策影响的假设。定性研究结果进一步结合供应商产品文献和营运案例研究，以突出实际实施考虑因素。最后，调查方法保障措施——包括纳入标准的透明度、专家意见的清晰审核追踪以及对解释性结论的敏感性检查——确保了建议在各种可能的市场情景下保持稳健。

最后，我们讨论了技术进步、政策演变和操作灵活性如何协调起来才能充分实现产前筛检的临床和商业性潜力。

摘要，非侵入性产前检测生态系统正处于曲折点，技术进步、医疗服务创新和政策转变正在重塑临床和商业模式。分析能力的增强和样本采集方法的创新正在扩大检测的可及性和临床效用，而支付方和法律规范的不断发展则提高了广泛应用的证据阈值。这些并行发展为致力于提供高品质产前护理的製造商、实验室和医疗系统创造了机会，也带来了复杂性。

随着相关人员应对成本调整和关税造成的供应链脆弱性等营运压力，那些在证据生成、供应韧性和以患者为中心的医疗服务方面进行投资的各方将处于更有利的地位。未来的道路需要临床、商业和政策部门协调行动，确保无创产前检测的进步转化为产前护理、公平获取服务以及家庭知情决策方面的重大改进。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 实施人工智慧驱动的生物资讯流程，以增强变异解释并降低 NIPT 中的假阳性率
  • 扩大 NIPT 检测范围，纳入罕见微缺失和单基因疾病筛检，以进行全面的产前风险评估
  • 采用新的样本采集方法，使用支援智慧型手机的行动采血装置在家中进行 NIPT 检测
  • 将多基因风险评分整合到非侵入性产前检测中以评估胎儿多因子疾病易感性
  • 定序技术公司与诊断实验室建立策略伙伴关係，加速 NIPT 测试的开发平臺
  • 不断变化的政策和报销格局影响北美和欧洲公共医疗体系对 NIPT 的采用
  • 开发非血液NIPT检测方法，使用母体唾液或尿液样本，简化胎儿DNA萃取工作流程
  • 直接面向消费者的 NIPT 平台的出现，提供家庭采集试剂套件和虚拟遗传咨询服务
  • 不断发展的伦理和监管框架，以解决扩展的 NIPT 产品组合中的偶然发现和资料隐私问题
  • 采用分子条码富集策略可降低定序成本并提高 NIPT 测试的分析灵敏度

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

8. 按检测类型分類的非侵入性产前检测市场

  • 非整倍体筛检
    • 13三体症（Patau症候群）
    • 18三体症（爱德华氏症候群）
    • 21三体症（唐氏症）
  • 微缺失症候群
    • 1p36缺失
    • 22q11.2缺失（DiGeorge症候群）
    • 哭泣综合症
  • 性染色体非整倍体（SCA）
    • 柯林菲特氏症（XXY）
    • 三X综合征（XXX）
    • 透纳氏症（单体X）
    • XYY综合症
  • 全基因组筛检

9. 非侵入性产前检测市场技术

  • 基于微阵列的分析
  • 次世代定序（NGS）
  • 聚合酵素链锁反应（PCR）
  • 滚圆放大器（RCA）

10. 按孕週分類的非侵入性产前检测市场

  • 第10-17週
  • 第18-23週
  • 23週或以上

第 11 章。 按交付方式分類的非侵入性产前检测市场

  • 家庭样本采集
  • 实验室测试服务
  • 就地检验

第 12 章非侵入性产前检测市场（按最终用户）

  • 诊断实验室
  • 医院
  • 专科诊所

13. 按地区分類的非侵入性产前检测市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第 14 章非侵入性产前检测市场（按类别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 按国家分類的非侵入性产前检测市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Illumina, Inc.
    • Natera, Inc.
    • Agilent Technologies, Inc.
    • BGI Group
    • BillionToOne, Inc.
    • Biora Therapeutics, Inc.
    • BioReference Laboratories, Inc.
    • Centogene NV
    • Eurofins Scientific SE
    • F.Hoffmann-La Roche Ltd.
    • GE HealthCare Technologies Inc.
    • Igenomix SLU by Vitrolife Group
    • Laboratory Corporation of America Holdings
    • Lilac Insights Pvt. Ltd.
    • MedGenome Labs Ltd.
    • Myriad Genetics, Inc.
    • Quest Diagnostics Incorporated
    • Ravgen Inc.
    • Sonic Healthcare USA
    • Thermo Fisher Scientific Inc.
    • Yourgene Health by Novacyt UK Holdings Limited
    • Labcorp Holdings Inc.
Product Code: MRR-036C5CF3B521

The Non-invasive Prenatal Testing Market is projected to grow by USD 14.52 billion at a CAGR of 11.05% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 6.27 billion
Estimated Year [2025] USD 6.93 billion
Forecast Year [2032] USD 14.52 billion
CAGR (%) 11.05%

Framing the modern non-invasive prenatal testing landscape by weaving together clinical advances, patient expectations, and operational challenges shaping prenatal diagnostics

Non-invasive prenatal testing has evolved from a niche screening adjunct to a central pillar of prenatal care, shaped by advances in sequencing, bioinformatics, and an increasingly patient-centric health ecosystem. Clinicians now rely on cell-free DNA analysis to inform diagnostic pathways earlier in pregnancy, while expectant parents expect clearer counseling and less invasive options. As a result, the clinical community and commercial stakeholders are navigating a rapidly changing interface where technological capability, regulatory oversight, and payer acceptance intersect.

Consequently, the landscape demands rigorous evidence generation and thoughtful integration of laboratory workflows with obstetric care. Laboratories are balancing precision and throughput, hospitals are recalibrating protocols for prenatal counseling, and specialty clinics are refining patient engagement models to reflect both clinical utility and ethical considerations. Moreover, as diagnostic sophistication increases, so does the responsibility to ensure equitable access, clarity of results, and robust post-test follow-up. This introduction frames the broader market forces and clinical imperatives that underpin the subsequent analysis and recommendations.

How rapid technological maturation, decentralization of sample collection, and evolving regulatory expectations are fundamentally redefining prenatal diagnostic care delivery

The last several years have seen transformative shifts in non-invasive prenatal testing driven by technological convergence and shifting care delivery models. Next-generation sequencing platforms and more sophisticated bioinformatic algorithms have expanded detection capabilities beyond common trisomies, enabling identification of a broader range of chromosomal abnormalities and microdeletions with increasing resolution. At the same time, improvements in assay design and laboratory automation have compressed turnaround times and improved reproducibility, allowing for faster clinical decision-making and more streamlined integration into prenatal workflows.

Simultaneously, the market is experiencing a movement toward decentralization of sample collection and patient engagement. At-home sample kits and point-of-care testing modalities are gaining traction, creating opportunities for earlier access and greater convenience, while also raising new questions around quality control, patient education, and data security. Alongside these delivery changes, regulatory bodies and payers are progressively refining coverage frameworks and evidence requirements. This regulatory maturation, together with expanded clinical validation studies, is encouraging broader clinical adoption but also raising the bar for manufacturers and laboratories in terms of clinical utility and cost-effectiveness. Taken together, these shifts are not merely incremental; they are redefining how prenatal screening is offered, interpreted, and acted upon across multiple points of care.

Evaluating the operational, supply chain, and payer-level consequences of new import tariffs that are reshaping cost structures and strategic sourcing decisions in prenatal diagnostics

The introduction of tariffs on certain imported laboratory equipment, consumables, and reagents in 2025 has introduced a new variable into the economics of non-invasive prenatal testing. For laboratories and device manufacturers that depend on global supply chains for sequencers, reagents, and precision optics, tariff-driven cost adjustments have translated into tighter operating margins and renewed scrutiny of procurement strategies. In many places, organizations have responded by revising inventory management practices, negotiating longer-term supplier contracts, and accelerating conversations around supply chain resilience and nearshoring.

Beyond immediate cost pressures, tariffs have catalyzed strategic thinking around localization of manufacturing and diversification of component sourcing. Companies with vertically integrated operations or those able to substitute domestically produced inputs have gained relative operational flexibility. In addition, the tariff environment has prompted greater collaboration between manufacturers and payers to reassess reimbursement constructs, as stakeholders align on how to preserve patient access without compromising clinical quality. Finally, the policy environment underscores the importance of transparent cost communication and proactive regulatory engagement to mitigate downstream effects on testing availability, laboratory consolidation, and innovation trajectories.

Granular segmentation analysis linking assay types, technology platforms, gestational timing, delivery models, and clinical end-users to reveal strategic opportunity zones

Insight into market segmentation clarifies where clinical need, technological capability, and service delivery intersect to create differentiated value propositions. Based on test type, the market is organized around aneuploidy screening that includes trisomies such as Trisomy 13 (Patau Syndrome), Trisomy 18 (Edwards Syndrome), and Trisomy 21 (Down Syndrome), microdeletion syndromes that cover conditions like 1p36 Deletion, 22q11.2 Deletion (DiGeorge Syndrome), and Cri-du-chat Syndrome, sex chromosome aneuploidies encompassing Klinefelter Syndrome (XXY), Triple X Syndrome (XXX), Turner Syndrome (Monosomy X), and XYY Syndrome, as well as whole-genome screening approaches that expand the detection envelope. Each test type imposes distinct requirements for analytical sensitivity, counseling complexity, and confirmatory workflows, which in turn influence laboratory architecture and clinical adoption.

From a technology standpoint, the competitive dynamics revolve around microarray-based analysis, next-generation sequencing, polymerase chain reaction techniques, and rolling circle amplification methods. Technologies differ not only in analytical throughput and cost per sample but also in bioinformatic complexity and validation expectations, thereby guiding purchasing priorities and partnership strategies. Considering gestation period, segmentation across 10-17 weeks, 18-23 weeks, and above 23 weeks shapes clinical utility, since earlier testing enables different counseling and management options compared with later gestational windows. Mode of delivery segmentation across at-home sample collection, laboratory-based testing services, and point-of-care testing highlights divergent operational models and patient experience trade-offs. Finally, end-user segmentation that includes diagnostic laboratories, hospitals, and specialty clinics captures how testing volumes, clinical pathways, and service level expectations vary, thereby affecting sales channels, payer interactions, and clinical education strategies. Integrated analysis across these segments reveals where innovation and commercial focus can yield the greatest clinical and economic impact.

Regional adoption patterns and policy nuances across the Americas, Europe Middle East & Africa, and Asia-Pacific that dictate differentiated market entry and service models

Regional dynamics continue to shape adoption patterns, regulatory expectations, and commercial strategies in non-invasive prenatal testing. In the Americas, mature reimbursement frameworks, high clinical adoption among obstetric providers, and a dynamic landscape of commercial laboratories drive a focus on clinical utility studies, payer engagement, and service differentiation. Market participants in this region often prioritize partnerships with healthcare systems and investments in rapid laboratory throughput to meet clinical demand while simultaneously addressing concerns around equitable access in underserved communities.

Conversely, Europe, Middle East & Africa presents a heterogeneous environment where regulatory regimes and payer models vary significantly by country, prompting tailored evidence generation and market entry approaches. In several European markets, centralized public healthcare systems emphasize cost-effectiveness and national guideline alignment, while in parts of the Middle East and Africa, infrastructure and access constraints necessitate strategies centered on capacity-building and clinician education. Meanwhile, Asia-Pacific reflects a mixture of rapid adoption in urban centers, growing private lab networks, and increasing investments in local manufacturing and genomics capabilities. In this region, early-mover providers are prioritizing localization of services, multilingual patient engagement, and collaborations with regional health authorities to scale access. Across all regions, cross-border collaborations, data privacy considerations, and the need for culturally appropriate counseling remain recurrent themes that companies must navigate thoughtfully.

Competitive dynamics driven by vertical integration, validation-led differentiation, strategic partnerships, and selective consolidation shaping corporate strategies in prenatal diagnostics

Competitive behavior among companies active in non-invasive prenatal testing is characterized by a mix of vertical integration, platform differentiation, and strategic partnerships. Leading diagnostics firms and clinical laboratories are investing in assay validation, bioinformatics refinement, and expanded clinical indications to strengthen evidentiary positioning. At the same time, collaborations between instrument manufacturers, reagent suppliers, and clinical service providers are becoming more common as organizations seek to bundle solutions that reduce implementation friction for hospital systems and large laboratory networks.

In parallel, smaller innovators are carving niche positions by focusing on at-home collection platforms, enhanced patient reporting interfaces, or specialized microdeletion panels. Consolidation activity is evident as market participants pursue acquisitions to secure intellectual property, expand geographic footprints, or accelerate entry into adjacent testing modalities. Importantly, regulatory compliance and third-party accreditation remain differentiators; companies that demonstrate rigorous clinical validation, transparent performance characteristics, and robust quality systems typically gain preferential consideration from institutional purchasers and payers. Overall, the competitive landscape rewards those that combine scientific rigor with scalable operations and a clear pathway to reimbursement.

Practical strategic priorities for diagnostic leaders to strengthen clinical validation, supply resilience, payer engagement, and patient-centric delivery models concurrently

Industry leaders must adopt a multi-pronged set of actions to sustain clinical credibility while capturing commercial upside. First, investing in rigorous clinical validation studies and real-world evidence programs will strengthen positioning with payers and clinicians and will facilitate broader guideline adoption. Second, diversifying supply chains and building stronger vendor relationships will mitigate exposure to import tariffs and component shortages, and firms should evaluate nearshoring or multi-supplier strategies where feasible to preserve operational continuity.

Third, organizations should prioritize patient-centric delivery models that improve access and comprehension, including expansion of at-home collection programs coupled with clinician-mediated counseling pathways. Fourth, strengthening payer engagement through evidence-based value dossiers and outcomes data will be critical to securing sustainable reimbursement. Concurrently, companies should pursue scalable automation in laboratories and invest in interoperable data systems to reduce turnaround times and lower per-test operational costs. Finally, consider strategic partnerships or targeted M&A to obtain missing capabilities-whether in bioinformatics, sample collection, or regional market access-thereby accelerating time to market and minimizing execution risk. These recommendations create an operational playbook that balances clinical rigor with commercial pragmatism.

A rigorous, multi-source research methodology combining expert interviews, clinical literature synthesis, and iterative validation to underpin credible market insights and recommendations

The research approach integrates primary stakeholder interviews, secondary literature synthesis, and methodological triangulation to ensure balanced, defensible conclusions. Primary research involved structured conversations with clinical geneticists, laboratory directors, obstetric leaders, and commercial executives to capture contemporary practice patterns, procurement priorities, and innovation roadmaps. These insights were complemented by a systematic review of peer-reviewed clinical studies, regulatory guidance, and published technical briefs to validate analytical performance attributes and clinical utility narratives.

Data were cross-checked through iterative validation sessions with subject-matter experts to refine assumptions about laboratory workflows, technology adoption hurdles, and regional policy implications. Qualitative findings were further contextualized with vendor product literature and operational case studies to highlight practical implementation considerations. Finally, methodological safeguards included transparency around inclusion criteria, a clear audit trail for expert inputs, and sensitivity checks on interpretative conclusions to ensure that recommendations remain robust across plausible market scenarios.

Concluding synthesis of how technological advances, policy evolution, and operational resilience must be aligned to realize the full clinical and commercial potential of prenatal screening

In summary, the non-invasive prenatal testing ecosystem stands at an inflection point where technological advances, delivery innovations, and policy shifts converge to reshape clinical practice and commercial models. Enhanced analytical capabilities and novel modes of sample collection are expanding access and clinical utility, while evolving payer and regulatory frameworks are raising the evidence threshold for broad adoption. These parallel developments create both opportunity and complexity for manufacturers, laboratories, and health systems seeking to deliver high-quality prenatal care.

As stakeholders respond to operational pressures such as tariff-induced cost adjustments and supply chain vulnerabilities, those who invest in evidence generation, supply resilience, and patient-centered delivery will be better positioned to lead. The path forward requires coordinated action across clinical, commercial, and policy fronts to ensure that advances in non-invasive prenatal testing translate into meaningful improvements in prenatal care, equitable access, and informed decision-making for families.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Implementation of AI-driven bioinformatics pipelines to enhance variant interpretation and reduce NIPT false positive rates
  • 5.2. Expansion of NIPT panels to include rare microdeletions and single gene disorder screening for comprehensive prenatal risk assessment
  • 5.3. Adoption of novel sample collection methods enabling at-home NIPT testing with smartphone-compatible mobile phlebotomy units
  • 5.4. Integration of polygenic risk scoring into non-invasive prenatal tests to assess multifactorial disease predisposition in fetuses
  • 5.5. Strategic partnerships between sequencing technology firms and diagnostic laboratories to accelerate NIPT assay development pipelines
  • 5.6. Policy and reimbursement landscape shifts influencing NIPT adoption in public healthcare systems across North America and Europe
  • 5.7. Development of non-blood based NIPT assays using maternal saliva or urine samples for simplified fetal DNA extraction workflows
  • 5.8. Emergence of direct-to-consumer NIPT platforms offering at-home collection kits and virtual genetic counseling services
  • 5.9. Ethical and regulatory frameworks evolving to address incidental findings and data privacy concerns in expanded NIPT portfolios
  • 5.10. Adoption of molecular barcode enrichment strategies to reduce sequencing costs and improve analytical sensitivity of NIPT assays

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Non-invasive Prenatal Testing Market, by Test Type

  • 8.1. Aneuploidy Screening
    • 8.1.1. Trisomy 13 (Patau Syndrome)
    • 8.1.2. Trisomy 18 (Edwards Syndrome)
    • 8.1.3. Trisomy 21 (Down Syndrome)
  • 8.2. Microdeletion Syndromes
    • 8.2.1. 1p36 Deletion
    • 8.2.2. 22q11.2 Deletion (DiGeorge Syndrome)
    • 8.2.3. Cri-du-chat Syndrome
  • 8.3. Sex Chromosome Aneuploidies (SCA)
    • 8.3.1. Klinefelter Syndrome (XXY)
    • 8.3.2. Triple X Syndrome (XXX)
    • 8.3.3. Turner Syndrome (Monosomy X)
    • 8.3.4. XYY Syndrome
  • 8.4. Whole-Genome Screening

9. Non-invasive Prenatal Testing Market, by By Technology

  • 9.1. Microarray-Based Analysis
  • 9.2. Next-Generation Sequencing (NGS)
  • 9.3. Polymerase Chain Reaction (PCR)
  • 9.4. Rolling Circle Amplification (RCA)

10. Non-invasive Prenatal Testing Market, by Gestation Period

  • 10.1. 10-17 Week
  • 10.2. 18-23 Week
  • 10.3. Above 23 Week

11. Non-invasive Prenatal Testing Market, by Mode of Delivery

  • 11.1. At-Home Sample Collection
  • 11.2. Laboratory-Based Testing Services
  • 11.3. Point-of-Care Testing

12. Non-invasive Prenatal Testing Market, by End-User

  • 12.1. Diagnostic Laboratories
  • 12.2. Hospitals
  • 12.3. Specialty Clinics

13. Non-invasive Prenatal Testing Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Non-invasive Prenatal Testing Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Non-invasive Prenatal Testing Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Illumina, Inc.
    • 16.3.2. Natera, Inc.
    • 16.3.3. Agilent Technologies, Inc.
    • 16.3.4. BGI Group
    • 16.3.5. BillionToOne, Inc.
    • 16.3.6. Biora Therapeutics, Inc.
    • 16.3.7. BioReference Laboratories, Inc.
    • 16.3.8. Centogene N.V.
    • 16.3.9. Eurofins Scientific SE
    • 16.3.10. F.Hoffmann-La Roche Ltd.
    • 16.3.11. GE HealthCare Technologies Inc.
    • 16.3.12. Igenomix S.L.U by Vitrolife Group
    • 16.3.13. Laboratory Corporation of America Holdings
    • 16.3.14. Lilac Insights Pvt. Ltd.
    • 16.3.15. MedGenome Labs Ltd.
    • 16.3.16. Myriad Genetics, Inc.
    • 16.3.17. Quest Diagnostics Incorporated
    • 16.3.18. Ravgen Inc.
    • 16.3.19. Sonic Healthcare USA
    • 16.3.20. Thermo Fisher Scientific Inc.
    • 16.3.21. Yourgene Health by Novacyt UK Holdings Limited
    • 16.3.22. Labcorp Holdings Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY GESTATION PERIOD, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY GESTATION PERIOD, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MODE OF DELIVERY, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MODE OF DELIVERY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY END-USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NON-INVASIVE PRENATAL TESTING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. NON-INVASIVE PRENATAL TESTING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. NON-INVASIVE PRENATAL TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY ANEUPLOIDY SCREENING, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY ANEUPLOIDY SCREENING, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY ANEUPLOIDY SCREENING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY ANEUPLOIDY SCREENING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY ANEUPLOIDY SCREENING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY ANEUPLOIDY SCREENING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY ANEUPLOIDY SCREENING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY ANEUPLOIDY SCREENING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TRISOMY 13 (PATAU SYNDROME), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TRISOMY 13 (PATAU SYNDROME), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TRISOMY 13 (PATAU SYNDROME), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TRISOMY 13 (PATAU SYNDROME), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TRISOMY 13 (PATAU SYNDROME), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TRISOMY 13 (PATAU SYNDROME), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TRISOMY 18 (EDWARDS SYNDROME), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TRISOMY 18 (EDWARDS SYNDROME), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TRISOMY 18 (EDWARDS SYNDROME), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TRISOMY 18 (EDWARDS SYNDROME), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TRISOMY 18 (EDWARDS SYNDROME), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TRISOMY 18 (EDWARDS SYNDROME), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TRISOMY 21 (DOWN SYNDROME), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TRISOMY 21 (DOWN SYNDROME), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TRISOMY 21 (DOWN SYNDROME), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TRISOMY 21 (DOWN SYNDROME), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TRISOMY 21 (DOWN SYNDROME), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TRISOMY 21 (DOWN SYNDROME), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MICRODELETION SYNDROMES, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MICRODELETION SYNDROMES, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MICRODELETION SYNDROMES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MICRODELETION SYNDROMES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MICRODELETION SYNDROMES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MICRODELETION SYNDROMES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MICRODELETION SYNDROMES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MICRODELETION SYNDROMES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY 1P36 DELETION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY 1P36 DELETION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY 1P36 DELETION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY 1P36 DELETION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY 1P36 DELETION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY 1P36 DELETION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY 22Q11.2 DELETION (DIGEORGE SYNDROME), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY 22Q11.2 DELETION (DIGEORGE SYNDROME), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY 22Q11.2 DELETION (DIGEORGE SYNDROME), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY 22Q11.2 DELETION (DIGEORGE SYNDROME), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY 22Q11.2 DELETION (DIGEORGE SYNDROME), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY 22Q11.2 DELETION (DIGEORGE SYNDROME), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY CRI-DU-CHAT SYNDROME, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY CRI-DU-CHAT SYNDROME, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY CRI-DU-CHAT SYNDROME, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY CRI-DU-CHAT SYNDROME, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY CRI-DU-CHAT SYNDROME, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY CRI-DU-CHAT SYNDROME, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY SEX CHROMOSOME ANEUPLOIDIES (SCA), 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY SEX CHROMOSOME ANEUPLOIDIES (SCA), 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY SEX CHROMOSOME ANEUPLOIDIES (SCA), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY SEX CHROMOSOME ANEUPLOIDIES (SCA), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY SEX CHROMOSOME ANEUPLOIDIES (SCA), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY SEX CHROMOSOME ANEUPLOIDIES (SCA), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY SEX CHROMOSOME ANEUPLOIDIES (SCA), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY SEX CHROMOSOME ANEUPLOIDIES (SCA), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY KLINEFELTER SYNDROME (XXY), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY KLINEFELTER SYNDROME (XXY), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY KLINEFELTER SYNDROME (XXY), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY KLINEFELTER SYNDROME (XXY), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY KLINEFELTER SYNDROME (XXY), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY KLINEFELTER SYNDROME (XXY), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TRIPLE X SYNDROME (XXX), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TRIPLE X SYNDROME (XXX), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TRIPLE X SYNDROME (XXX), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TRIPLE X SYNDROME (XXX), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TRIPLE X SYNDROME (XXX), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TRIPLE X SYNDROME (XXX), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TURNER SYNDROME (MONOSOMY X), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TURNER SYNDROME (MONOSOMY X), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TURNER SYNDROME (MONOSOMY X), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TURNER SYNDROME (MONOSOMY X), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TURNER SYNDROME (MONOSOMY X), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TURNER SYNDROME (MONOSOMY X), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY XYY SYNDROME, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY XYY SYNDROME, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY XYY SYNDROME, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY XYY SYNDROME, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY XYY SYNDROME, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY XYY SYNDROME, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY WHOLE-GENOME SCREENING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY WHOLE-GENOME SCREENING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY WHOLE-GENOME SCREENING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY WHOLE-GENOME SCREENING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY WHOLE-GENOME SCREENING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY WHOLE-GENOME SCREENING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MICROARRAY-BASED ANALYSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MICROARRAY-BASED ANALYSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MICROARRAY-BASED ANALYSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MICROARRAY-BASED ANALYSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MICROARRAY-BASED ANALYSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MICROARRAY-BASED ANALYSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY ROLLING CIRCLE AMPLIFICATION (RCA), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY ROLLING CIRCLE AMPLIFICATION (RCA), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY ROLLING CIRCLE AMPLIFICATION (RCA), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY ROLLING CIRCLE AMPLIFICATION (RCA), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY ROLLING CIRCLE AMPLIFICATION (RCA), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY ROLLING CIRCLE AMPLIFICATION (RCA), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY GESTATION PERIOD, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY GESTATION PERIOD, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY 10-17 WEEK, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY 10-17 WEEK, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY 10-17 WEEK, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY 10-17 WEEK, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY 10-17 WEEK, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY 10-17 WEEK, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY 18-23 WEEK, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY 18-23 WEEK, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY 18-23 WEEK, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY 18-23 WEEK, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY 18-23 WEEK, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY 18-23 WEEK, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY ABOVE 23 WEEK, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY ABOVE 23 WEEK, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY ABOVE 23 WEEK, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY ABOVE 23 WEEK, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY ABOVE 23 WEEK, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY ABOVE 23 WEEK, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MODE OF DELIVERY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MODE OF DELIVERY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY AT-HOME SAMPLE COLLECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY AT-HOME SAMPLE COLLECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY AT-HOME SAMPLE COLLECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY AT-HOME SAMPLE COLLECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY AT-HOME SAMPLE COLLECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY AT-HOME SAMPLE COLLECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY LABORATORY-BASED TESTING SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY LABORATORY-BASED TESTING SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY LABORATORY-BASED TESTING SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY LABORATORY-BASED TESTING SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY LABORATORY-BASED TESTING SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY LABORATORY-BASED TESTING SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY POINT-OF-CARE TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY POINT-OF-CARE TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY POINT-OF-CARE TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY POINT-OF-CARE TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY POINT-OF-CARE TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY POINT-OF-CARE TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. AMERICAS NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 186. AMERICAS NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 187. AMERICAS NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 188. AMERICAS NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 189. AMERICAS NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY ANEUPLOIDY SCREENING, 2018-2024 (USD MILLION)
  • TABLE 190. AMERICAS NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY ANEUPLOIDY SCREENING, 2025-2032 (USD MILLION)
  • TABLE 191. AMERICAS NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MICRODELETION SYNDROMES, 2018-2024 (USD MILLION)
  • TABLE 192. AMERICAS NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MICRODELETION SYNDROMES, 2025-2032 (USD MILLION)
  • TABLE 193. AMERICAS NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY SEX CHROMOSOME ANEUPLOIDIES (SCA), 2018-2024 (USD MILLION)
  • TABLE 194. AMERICAS NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY SEX CHROMOSOME ANEUPLOIDIES (SCA), 2025-2032 (USD MILLION)
  • TABLE 195. AMERICAS NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 196. AMERICAS NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 197. AMERICAS NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY GESTATION PERIOD, 2018-2024 (USD MILLION)
  • TABLE 198. AMERICAS NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY GESTATION PERIOD, 2025-2032 (USD MILLION)
  • TABLE 199. AMERICAS NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MODE OF DELIVERY, 2018-2024 (USD MILLION)
  • TABLE 200. AMERICAS NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MODE OF DELIVERY, 2025-2032 (USD MILLION)
  • TABLE 201. AMERICAS NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 202. AMERICAS NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 203. NORTH AMERICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. NORTH AMERICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. NORTH AMERICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 206. NORTH AMERICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY ANEUPLOIDY SCREENING, 2018-2024 (USD MILLION)
  • TABLE 208. NORTH AMERICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY ANEUPLOIDY SCREENING, 2025-2032 (USD MILLION)
  • TABLE 209. NORTH AMERICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MICRODELETION SYNDROMES, 2018-2024 (USD MILLION)
  • TABLE 210. NORTH AMERICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MICRODELETION SYNDROMES, 2025-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY SEX CHROMOSOME ANEUPLOIDIES (SCA), 2018-2024 (USD MILLION)
  • TABLE 212. NORTH AMERICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY SEX CHROMOSOME ANEUPLOIDIES (SCA), 2025-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 214. NORTH AMERICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 215. NORTH AMERICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY GESTATION PERIOD, 2018-2024 (USD MILLION)
  • TABLE 216. NORTH AMERICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY GESTATION PERIOD, 2025-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MODE OF DELIVERY, 2018-2024 (USD MILLION)
  • TABLE 218. NORTH AMERICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MODE OF DELIVERY, 2025-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 220. NORTH AMERICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. LATIN AMERICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. LATIN AMERICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 224. LATIN AMERICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 225. LATIN AMERICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY ANEUPLOIDY SCREENING, 2018-2024 (USD MILLION)
  • TABLE 226. LATIN AMERICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY ANEUPLOIDY SCREENING, 2025-2032 (USD MILLION)
  • TABLE 227. LATIN AMERICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MICRODELETION SYNDROMES, 2018-2024 (USD MILLION)
  • TABLE 228. LATIN AMERICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MICRODELETION SYNDROMES, 2025-2032 (USD MILLION)
  • TABLE 229. LATIN AMERICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY SEX CHROMOSOME ANEUPLOIDIES (SCA), 2018-2024 (USD MILLION)
  • TABLE 230. LATIN AMERICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY SEX CHROMOSOME ANEUPLOIDIES (SCA), 2025-2032 (USD MILLION)
  • TABLE 231. LATIN AMERICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 232. LATIN AMERICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 233. LATIN AMERICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY GESTATION PERIOD, 2018-2024 (USD MILLION)
  • TABLE 234. LATIN AMERICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY GESTATION PERIOD, 2025-2032 (USD MILLION)
  • TABLE 235. LATIN AMERICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MODE OF DELIVERY, 2018-2024 (USD MILLION)
  • TABLE 236. LATIN AMERICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MODE OF DELIVERY, 2025-2032 (USD MILLION)
  • TABLE 237. LATIN AMERICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 238. LATIN AMERICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY ANEUPLOIDY SCREENING, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY ANEUPLOIDY SCREENING, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MICRODELETION SYNDROMES, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MICRODELETION SYNDROMES, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY SEX CHROMOSOME ANEUPLOIDIES (SCA), 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY SEX CHROMOSOME ANEUPLOIDIES (SCA), 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY GESTATION PERIOD, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY GESTATION PERIOD, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MODE OF DELIVERY, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MODE OF DELIVERY, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY ANEUPLOIDY SCREENING, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY ANEUPLOIDY SCREENING, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MICRODELETION SYNDROMES, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MICRODELETION SYNDROMES, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY SEX CHROMOSOME ANEUPLOIDIES (SCA), 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY SEX CHROMOSOME ANEUPLOIDIES (SCA), 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY GESTATION PERIOD, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY GESTATION PERIOD, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MODE OF DELIVERY, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY MODE OF DELIVERY, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 275. MIDDLE EAST NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. MIDDLE EAST NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. MIDDLE EAST NON-INVASIVE PRENATAL TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 278. MIDDLE EAST NON-I